Aldeyra Therapeutics Dividend
Dividend criteria checks 0/6
Aldeyra Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$0.51 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Revisiting Aldeyra Therapeutics
Sep 29Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Jun 01Aldeyra Therapeutics EPS beats by $0.01
May 06Aldeyra's conjunctivitis treatment meets late-stage study main goals
Apr 27How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?
Feb 23Aldeyra announces reproxalap's late-stage dry eye disease trial design
Feb 04Aldeyra initiates stock offering
Jan 13Aldeyra rated buy at Citi on reproxalap trial results
Jan 08Aldeyra's reproxalap improves dry eye disease symptoms, run-in cohort shows
Jan 07How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Do Institutions Own?
Jan 01
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ALDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALDX's dividend payments have been increasing.
Dividend Yield vs Market
| Aldeyra Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ALDX) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (ALDX) | 0% |
Notable Dividend: Unable to evaluate ALDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ALDX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALDX has not reported any payouts.